We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.63B
AUM Growth
-$1.1B
Cap. Flow
-$741M
Cap. Flow %
-20.41%
Top 10 Hldgs %
50.26%
Holding
130
New
22
Increased
12
Reduced
43
Closed
31

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$43.3M
2
PODD icon
Insulet
PODD
+$22.7M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$21.9M
4
SEPN
Septerna Inc
SEPN
+$17.7M
5
PEN icon
Penumbra
PEN
+$16.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$88.3M
2
BHVN icon
Biohaven
BHVN
+$74.2M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$50.4M
4
APGE
Apogee Therapeutics
APGE
+$49.4M
5
APLT
Applied Therapeutics
APLT
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CATX icon
76
Perspective Therapeutics
CATX
$312M
$3.8M 0.1%
+1,190,263
New +$9.72M
LCTX icon
77
Lineage Cell Therapeutics
LCTX
$268M
$3.64M 0.1%
+7,236,843
New +$5.31M
BDSX icon
78
Biodesix
BDSX
$292M
$3.33M 0.09%
108,694
– –
LONA
79
LeonaBio Inc
LONA
$68.2M
$3.17M 0.09%
540,296
– –
PEPG icon
80
PepGen
PEPG
$200M
$3.14M 0.09%
829,536
-580,902
-41% -$3.62M
IBRX icon
81
ImmunityBio
IBRX
$8.63B
$3.13M 0.09%
+1,221,734
New +$5.09M
BCYC
82
Bicycle Therapeutics
BCYC
$257M
$2.76M 0.08%
197,108
-58,886
-23% -$1.26M
LYRA
83
DELISTED
LYRA THERAPEUTICS INC
LYRA
$2.63M 0.07%
255,151
– –
VRCA icon
84
Verrica Pharmaceuticals
VRCA
$78.7M
$2.27M 0.06%
324,967
-384,951
-54% -$4.23M
FBRX
85
DELISTED
Forte Biosciences
FBRX
$2.17M 0.06%
95,742
– –
SCPH
86
DELISTED
scPharmaceuticals
SCPH
$1.77M 0.05%
+500,000
New +$1.92M
TRIB
87
Trinity Biotech
TRIB
$5.96M
$1.58M 0.04%
59,667
-333
-0.6% -$13.4K
TRAW icon
88
Traws Pharma
TRAW
$8.13M
$1.46M 0.04%
+164,157
New +$914K
FULC icon
89
Fulcrum Therapeutics
FULC
$288M
$1.12M 0.03%
+238,000
New +$878K
LXEO icon
90
Lexeo Therapeutics
LXEO
$339M
$920K 0.03%
139,835
– –
NVAX icon
91
PUT
Novavax
NVAX
$1.52B
$804K 0.02%
100,000
– –
NBTX
92
Nanobiotix
NBTX
$1.79B
$764K 0.02%
266,093
-288,973
-52% -$1.16M
APLT
93
DELISTED
Applied Therapeutics
APLT
$736K 0.02%
860,000
-7,145,000
-89% -$44.8M
ENSC icon
94
Ensysce Biosciences
ENSC
$8.79M
$705K 0.02%
+86,666
New +$597K
DCTH icon
95
Delcath Systems
DCTH
$561M
$602K 0.02%
+50,000
New +$528K
PYXS icon
96
Pyxis Oncology
PYXS
$278M
$294K 0.01%
188,462
-320,000
-63% -$923K
APYX icon
97
Apyx Medical
APYX
$125M
$237K 0.01%
+150,000
New +$210K
RVMDW icon
98
Revolution Medicines Inc Warrant
RVMDW
$125M
$45K ﹤0.01%
250,000
– –
SRZNW
99
DELISTED
Surrozen Inc Warrant
SRZNW
$3.57K ﹤0.01%
166,666
– –
ABSI icon
100
Absci
ABSI
$1.36B
– –
-700,000
Closed -$2.67M
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Perceptive Advisors held 130 positions worth $3.63B, down 23% from $4.73B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $741M in Q4 2024, closing 31 positions and reducing 43 holdings. Its most notable exit was Biohaven, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Janux Therapeutics worth $43.8M.

  • Perceptive Advisors's largest Q4 2024 buy was Janux Therapeutics: 817,895 shares worth $43.8M.
  • Perceptive Advisors added most to Insulet in Q4 2024, an estimated $22.7M increase.
  • Perceptive Advisors's biggest Q4 2024 reduction was Soleno Therapeutics, cutting an estimated $88.3M.
  • Perceptive Advisors fully exited Biohaven in Q4 2024, selling an estimated $74.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.63B portfolio in Q4 2024.
  • Perceptive Advisors opened 22 new positions and closed 31 in Q4 2024.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $3.63B.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.